Hepatitis C treatment among racial and ethnic groups in the IDEAL trial.

Muir, A J; Hu, K-Q; Gordon, S C; Koury, K; Boparai, N; Noviello, S; Albrecht, J K; Sulkowski, M S; McCone, J

Muir, A J; Hu, K-Q; Gordon, S C; Koury, K; Boparai, N; Noviello, S; Albrecht, J K; Sulkowski, M S; McCone, J.

Affiliation

Muir AJ; Duke Clinical Research Institute and Division of Gastroenterology, Duke University Medical Center, Durham, NC 27701, USA. muir0002@mc.duke.edu

J Viral Hepat ; 18(4): e134-43, 2011 Apr.

Article in En | MEDLINE | ID: mdl-21108699

Subject(s)

Antiviral Agents/administration & dosage; Ethnicity; Hepatitis C, Chronic/drug therapy; Racial Groups; Adult; Female; Hepacivirus/isolation & purification; Humans; Interferon alpha-2; Interferon-alpha/administration & dosage; Male; Middle Aged; Polyethylene Glycols/administration & dosage; Recombinant Proteins; Ribavirin/administration & dosage; Treatment Outcome; United States; Viral Load

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Antiviral Agents / Ethnicity / Hepatitis C, Chronic / Racial Groups Type of study: Clinical_trials / Prognostic_studies Limits: Adult / Female / Humans / Male / Middle aged Country/Region as subject: America do norte Language: En Year: 2011 Type: Article

Fulltext

XML

PubMed Links

Search on Google